



SOFIE
From start to clinic

A Target of Opportunity – Shaping the Future of FAPI*

TIME: Sunday, June 22, 2025, 6:30-8:30pm
ROOM: 2nd level, Room R06-R07

VENUE: Ernest N. Morial Convention Center
SNMMI 2025 Annual Meeting, New Orleans, LA
Refreshments will be provided

In this informative session, we will explore the landscape of FAPI as a diagnostic radiopharmaceutical, specifically understanding the clinical need, progress of clinical trials and use cases. We will also dive into FAP targeting in therapy with a panel of key industry representatives.

SCIENTIFIC AGENDA	SPEAKERS
FAP Targeting in Therapy (panel)	Moderated by: Elcin Zan, MD , Cleveland Clinic Featuring industry representatives: <ul style="list-style-type: none">• Lilly• Novartis• Perspective• Precirix
Unmet Needs in Gastrointestinal Cancers	Matthew Strickland, MD Massachusetts General Hospital
Clinical Trial Site Set-up - Lessons Learned	Shadi Esfahani, MD, MPH Massachusetts General Hospital
SOFIE's [¹⁸ F]FAPI-74 Clinical Trials: Summary of Phase 2 and Plans for Phase 3	Sherly Mosessian, PhD Chief Scientific Officer, SOFIE
Name the Trials!	All
Q&A	All

*FAPI is investigational and has not been approved by the U.S. Food and Drug Administration (FDA). FAPI's safety and efficacy have not been established. This session is provided for informational purposes only and is intended solely for use by healthcare professionals, clinical trial investigators, and regulatory authorities. It is not intended as medical advice or an offer for sale or commercial promotion. Any use of FAPI is subject to applicable regulatory approval processes and clinical trial protocols.